Skip Nav Destination
Issues
December 2001
ISSN 1078-0432
EISSN 1557-3265
Issue Sections
The Biology Behind
Advances in Brief
Molecular Oncology, Markers, Clinical Correlates
Mesothelin Is Overexpressed in the Vast Majority of Ductal Adenocarcinomas of the Pancreas: Identification of a New Pancreatic Cancer Marker by Serial Analysis of Gene Expression (SAGE)1
Pedram Argani; Christine Iacobuzio-Donahue; Byungwoo Ryu; Christophe Rosty; Michael Goggins; Robb E. Wilentz; Selva R. Murugesan; Steven D. Leach; Elizabeth Jaffee; Charles J. Yeo; John L. Cameron; Scott E. Kern; Ralph H. Hruban
Experimental Therapeutics, Preclinical Pharmacology
Research Articles
Clinical Trials
A Phase I and Pharmacological Study of the Farnesyl Protein Transferase Inhibitor L-778,123 in Patients with Solid Malignancies1
Carolyn D. Britten; Eric K. Rowinsky; Steven Soignet; Amita Patnaik; Siu-Long Yao; Paul Deutsch; Yih Lee; Robert B. Lobell; Kathryn E. Mazina; Heather McCreery; Sandy Pezzuli; David Spriggs
A Phase I Dose-finding Study of Combined Treatment with an Antisense Bcl-2 Oligonucleotide (Genasense) and Mitoxantrone in Patients with Metastatic Hormone-refractory Prostate Cancer1
Kim N. Chi; Martin E. Gleave; Richard Klasa; Nevin Murray; Cicely Bryce; Daniel E. Lopes de Menezes; Susan D’Aloisio; Anthony W. Tolcher
Doxorubicin Followed by Sequential Paclitaxel and Cyclophosphamide versus Concurrent Paclitaxel and Cyclophosphamide: 5-Year Results of a Phase II Randomized Trial of Adjuvant Dose-dense Chemotherapy for Women with Node-positive Breast Carcinoma
Monica N. Fornier; Andrew D. Seidman; Maria Theodoulou; Mary Ellen Moynahan; Violante Currie; Mark Moasser; Nancy Sklarin; Theresa Gilewski; Gabriella D’Andrea; Rori Salvaggio; Kathy S. Panageas; Larry Norton; Clifford Hudis
Induction of Cellular Immune Responses to Tumor Cells and Peptides in Colorectal Cancer Patients by Vaccination with SART3 Peptides1
Yoshiaki Miyagi; Nobue Imai; Teruo Sasatomi; Akira Yamada; Takashi Mine; Kazuko Katagiri; Masami Nakagawa; Akira Muto; Shinya Okouchi; Hiroharu Isomoto; Kazuo Shirouzu; Hideaki Yamana; Kyogo Itoh
Phase I Study of Topoisomerase I Inhibitor Exatecan Mesylate (DX-8951f) Given as Weekly 24-Hour Infusions Three of Every Four Weeks
Sunil Sharma; Nancy Kemeny; Gary K. Schwartz; David Kelsen; Eileen O’Reilly; David Ilson; John Coyle; Robert L. De Jager; Martin P. Ducharme; Sarah Kleban; Ellen Hollywood; Leonard B. Saltz
Molecular Oncology, Markers, Clinical Correlates
Prognostic Impact of P53 Status, TLS-CHOP Fusion Transcript Structure, and Histological Grade in Myxoid Liposarcoma: A Molecular and Clinicopathologic Study of 82 Cases1
Cristina R. Antonescu; Sylvia J. Tschernyavsky; Ramona Decuseara; Denis H. Leung; James M. Woodruff; Murray F. Brennan; Julia A. Bridge; James R. Neff; John R. Goldblum; Marc Ladanyi
HER-2/neu Overexpression As a Poor Prognostic Factor for Patients with Metastatic Breast Cancer undergoing High-dose Chemotherapy with Autologous Stem Cell Transplantation
Young S. Kim; Sergej N. Konoplev; Filippo Montemurro; Emma Hoy; Terry L. Smith; Gabriela Rondón; Richard E. Champlin; Aysegul A. Sahin; Naoto T. Ueno
Actual Invasive Potential of Human Hepatocellular Carcinoma Revealed by in Situ Gelatin Zymography1
Toshihiko Kaneyoshi; Harushige Nakatsukasa; Toshihiro Higashi; Keishi Fujiwara; Ichiro Naito; Kazuhiro Nouso; Kazuya Kariyama; Yoshiyuki Kobayashi; Masayuki Uemura; Shin-ichiro Nakamura; Yoshiaki Iwasaki; Takao Tsuji
Mucin (MUC) Gene Expression in Human Pancreatic Adenocarcinoma and Chronic Pancreatitis: A Potential Role of MUC4 as a Tumor Marker of Diagnostic Significance1
Mahefatiana Andrianifahanana; Nicolas Moniaux; Bruno M. Schmied; Jörg Ringel; Helmut Friess; Michael A. Hollingsworth; Markus W. Büchler; Jean-Pierre Aubert; Surinder K. Batra
Nuclear Factor-κB p65 (RelA) Transcription Factor Is Constitutively Activated in Human Gastric Carcinoma Tissue
Nobuhiko Sasaki; Takashi Morisaki; Kentaro Hashizume; Takashi Yao; Masazumi Tsuneyoshi; Hirokazu Noshiro; Kenjiro Nakamura; Takeharu Yamanaka; Akihiko Uchiyama; Masao Tanaka; Mitsuo Katano
Experimental Therapeutics, Preclinical Pharmacology
Oral Administration of a Novel Taxane, an Antisense Oligonucleotide Targeting Protein Kinase A, and the Epidermal Growth Factor Receptor Inhibitor Iressa Causes Cooperative Antitumor and Antiangiogenic Activity1
Giampaolo Tortora; Rosa Caputo; Vincenzo Damiano; Gabriella Fontanini; Davide Melisi; Bianca Maria Veneziani; Franco Zunino; A. Raffaele Bianco; Fortunato Ciardiello
Identification of a Novel Membrane Protein, HP59, with Therapeutic Potential as a Target of Tumor Angiogenesis1
Changlin Fu; Smriti Bardhan; Nicolae D. Cetateanu; Barbara D. Wamil; Yufen Wang; He-Ping Yan; Ergang Shi; Clint Carter; Christo Venkov; F. Michael Yakes; David L. Page; R. Stephen Lloyd; Ray L. Mernaugh; Carl G. Hellerqvist
Glioma Cells Deficient in Urokinase Plaminogen Activator Receptor Expression Are Susceptible to Tumor Necrosis Factor-α-related Apoptosis-inducing Ligand-induced Apoptosis1
Bhavani Krishnamoorthy; Bryant Darnay; Bharat Aggarwal; Dzung H. Dinh; Gregory Kouraklis; William C. Olivero; Meena Gujrati; Jasti S. Rao
High Levels of HER-2 Expression Alter the Ability of Epidermal Growth Factor Receptor (EGFR) Family Tyrosine Kinase Inhibitors to Inhibit EGFR Phosphorylation in Vivo
James G. Christensen; Randall E. Schreck; Emily Chan; Xueyan Wang; Chris Yang; Luna Liu; Jean Cui; Li Sun; James Wei; Julie M. Cherrington; Dirk B. Mendel
Cancer Biology, Immunology, Cytokines
Letter to the Editor
Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer
Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: Summary Consensus Statement1
Aman U. Buzdar; Steven E. Come; Angela Brodie; Matthew Ellis; Paul E. Goss; James N. Ingle; Stephen R. D. Johnston; Adrian V. Lee; C. Kent Osborne; Victor G. Vogel; Carol S. Hart
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.